

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**MicroPort Scientific Corporation**

**微創醫療科學有限公司\***

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock code: 00853)**

**FURTHER ANNOUNCEMENT  
DISCLOSEABLE TRANSACTION  
CAPITAL INCREASE TO A SUBSIDIARY**

Reference is made to the announcement of the Company dated 31 August 2020 (the “**Announcement**”) in relation to the capital increase to the Subsidiary. Unless otherwise provided, capitalized terms used in this announcement shall have the same meaning as those used in the Announcement.

The Company would like to provide the following further information in respect of certain Investors for the reference of the shareholders and investors of the Company.

**Investor B**

Investor B, Tianjin Ronghao Enterprise Management Partnership (LLP), is held as to 99.86% interest by Panmao (Shanghai) Investment Center (LLP), which is in turn held by 46 limited partners, none of which holds 30% or more interest in Panmao (Shanghai) Investment Center (LLP). The general partner of Panmao (Shanghai) Investment Center (LLP) is a wholly-owned subsidiary of CITIC Private Equity Funds Management Co., Ltd. Panmao (Shanghai) Investment Center (LLP) focuses on equity investment opportunities in core industries such as industrial energy, medical services, leisure consumption, and financial services, with further focuses on minority equity investments in emerging industries such as technology, the Internet, and medicine.

**Investor C**

Investor C, Jiaxing Biolink Hongrun Venture Capital LLP, has 10 limited partners, none of which holds 30% or more interest in Investor C. Investor C is a professional private investment fund established by experienced investors in the healthcare industry. Its investment philosophy focuses on value investing and long-term strategic investment. Its investment scope covers global high-end medical equipment and consumables, biomedicine, innovative treatments, domestic medical services and other subsectors.

## **Investor E**

Investor E, Yifang Huida Venture Capital (Guangdong) Partnership (Limited Partnership), has 49 limited partners and 1 general partner. The 49 limited partners are all individuals, the general partner is a professional investment management company. None of the limited partners in Investor E holds 10% or more interest in Investor E. Investor E invests directly or indirectly in innovative medical enterprises, including equity investments in unlisted company, private equity funds, and partnership shares.

## **Investor F**

Investor F, Yifang Yida (Guangdong) Investment Partnership (Limited Partnership), has 1 limited partner and 1 general partner. The limited partner is 吳宏, who holds 99.98% interest. Investor F focuses on investment in the innovative medical sector.

By Order of the Board  
**MicroPort Scientific Corporation**  
**Dr. Zhaohua Chang**  
*Chairman*

Shanghai, the PRC, 14 September 2020

*As at the date of this announcement, the executive Director is Dr. Zhaohua Chang; the non-executive Directors are Mr. Norihiro Ashida, Dr. Yasuhisa Kurogi and Mr. Hongliang Yu; and the independent non-executive Directors are Mr. Jonathan H. Chou, Dr. Guoen Liu and Mr. Chunyang Shao.*

*\* For identification purpose only*